Dr. Chih-Tsung Yang is a THRF EMCR Fellow at the Future Industries Institute. His interdisciplinary research expertise is centred on the fields of biomaterials, biosensing, microfluidics and organ-on-a-chip models. His current research is focused on the development of bioengineered human organs-on-a-chip models to evaluate the therapeutic efficiency of nanomedicine and radiation therapy protocols.
Dr. Yang is currently leading an ambitious research program “Towards Precision Cancer Radiotherapy: Development of a Radiogenomic Tool through Patient-Derived Tumour on-Chips Reconstructing the Tumour Microenvironment”. His most recent work has been focused on the development of bioengineered tumour/tissue models aimed at providing new insight of the effect of ionizing radiation and, ultimately, at informing the design of better and safer radiotherapy algorithms. He initiated and coordinated the approval of the MOU between UniSA and Chang Gung University/Chang Gung Memorial Hospital (CGMH, Taiwan) in the field of proton beam therapy. He is also leading and coordinating several research projects with the proton beam therapy centre at CGMH.
Prior to the start of his PhD, he significantly contributed to the liquid biopsy technology that underpinned the successful spin-off of CellMax Life ($15 million from VCs). As an emerging leader in his field, he contributed directly to more than 30 publications in high-quality peer-reviewed journals, which is evidenced by the fact that 25 are published in Q1 journals in their field. Dr. Yang is actively engaged in his research community and is regularly invited to serve as a reviewer for peer-reviewed scientific journals (ACS Biomaterials Science & Engineering, ACS Applied Materials and Interfaces, Sensors, Optical Materials, Plos One and Applied Sciences). He is the UniSA node project leader of the signature project “Development of bioengineered multicellular systems” of the ARC Centre of Excellence for Convergent Bio-Nano Science &Technology (CBNS).